Trial Profile

CA-4948-104: A Ph1 Study of Emavusertib in AML CR MRD+ Patients Currently Receiving Azacitidine and Venetoclax

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emavusertib (Primary) ; Azacitidine; Venetoclax
Indications Acute myeloid leukaemia
Focus Adverse reactions
Sponsors Curis

Most Recent Events

01 Jun 2026 Status changed from recruiting to active, no longer recruiting.
19 Mar 2026 According to a Curis media release, Christina Papayannidis, MD, IRCCS Azienda Ospedaliero Universitaria di Bologna, presented a poster with initial clinical data in frontline AML at the 67th ASH Annual Meeting in December 2025.
09 Dec 2025 According to a Curis media release, data from the trial were presented in a poster presentation at the 67th ASH Annual Meeting (ASH).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com